📊 RGEN Key Takeaways
Is Repligen Corp. (RGEN) a Good Investment?
RGEN demonstrates solid fundamentals with 16.4% revenue growth, exceptional 291.6% net income growth, and an excellent liquidity position (current ratio 9.20x) backed by $582.6M cash. However, thin margins (4.3% net margin, 8.2% operating margin) and weak returns on equity/assets (0.4% ROE, 0.3% ROA) indicate the company prioritizes cash accumulation over profitability optimization.
Repligen is growing double-digits (+16.4% YoY) with a sharp rebound in profitability and solid free cash flow (12.7% margin), backed by strong liquidity. However, very low gross margin (8.2%), muted returns (ROE 2.3%), and thin interest coverage (2.4x) point to weak earnings quality. A neutral stance is warranted until margins recover and interest coverage improves.
Why Buy Repligen Corp. Stock? RGEN Key Strengths
- Strong revenue growth trajectory at 16.4% YoY in competitive biotech sector
- Exceptional net income growth of 291.6% YoY demonstrating improving operational leverage
- Fortress balance sheet: $582.6M cash, 0.26x debt-to-equity ratio, and 9.20x current ratio providing substantial financial flexibility
- Consistent free cash flow generation of $23.6M with healthy 12.1% FCF margin
- Robust liquidity (current 8.37x, quick 7.12x) with $566M cash
- Healthy free cash flow ($93.9M; 12.7% margin)
- Revenue growth +16.4% YoY with significant net income rebound
RGEN Stock Risks: Repligen Corp. Investment Risks
- Net profit margin of only 4.3% and operating margin of 8.2% suggest limited pricing power or high operational costs relative to revenue
- Extremely low return metrics (ROE 0.4%, ROA 0.3%) indicate inefficient capital deployment despite strong balance sheet
- The 291.6% net income growth may be unsustainable if driven by one-time benefits or cost cuts rather than core business expansion
- Interest coverage ratio of 2.7x provides only modest buffer if operating conditions deteriorate or rates increase
- Excess liquidity (9.20x current ratio) suggests capital not being productively deployed in growth initiatives or shareholder returns
- Very low gross margin (8.2%) indicates pricing/COGS pressure
- Low ROE (2.3%) and ROA (1.7%) suggest inefficient capital use
- Interest coverage of 2.4x leaves limited cushion if earnings soften
Key Metrics to Watch
- Operating margin trend and sustainability of net income growth in subsequent quarters
- Return on equity improvement trajectory and capital allocation strategy
- Organic revenue growth contribution versus any M&A-driven gains
- Free cash flow conversion rate and management's deployment plans for accumulated cash
- Gross margin %
- Interest coverage
Repligen Corp. (RGEN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.20x current ratio provides a solid financial cushion.
RGEN Profit Margin, ROE & Profitability Analysis
RGEN vs Healthcare Sector: How Repligen Corp. Compares
How Repligen Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Repligen Corp. Stock Overvalued? RGEN Valuation Analysis 2026
Based on fundamental analysis, Repligen Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Repligen Corp. Balance Sheet: RGEN Debt, Cash & Liquidity
RGEN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Repligen Corp.'s revenue has grown significantly by 10% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.63 reflects profitable operations.
RGEN Revenue Growth, EPS Growth & YoY Performance
RGEN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $169.2M | $5.8M | $0.10 |
| Q3 2025 | $154.9M | -$654.0K | $-0.01 |
| Q2 2025 | $158.8M | $5.7M | $0.10 |
| Q1 2025 | $153.2M | $3.3M | $0.06 |
| Q3 2024 | $141.2M | -$654.0K | $-0.01 |
| Q2 2024 | $154.1M | $3.3M | $0.06 |
| Q1 2024 | $151.3M | $2.1M | $0.04 |
| Q3 2023 | $141.2M | $18.2M | $0.32 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Repligen Corp. Dividends, Buybacks & Capital Allocation
RGEN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Repligen Corp. (CIK: 0000730272)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RGEN
What is the AI rating for RGEN?
Repligen Corp. (RGEN) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (HOLD) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RGEN's key strengths?
Claude: Strong revenue growth trajectory at 16.4% YoY in competitive biotech sector. Exceptional net income growth of 291.6% YoY demonstrating improving operational leverage. ChatGPT: Robust liquidity (current 8.37x, quick 7.12x) with $566M cash. Healthy free cash flow ($93.9M; 12.7% margin).
What are the risks of investing in RGEN?
Claude: Net profit margin of only 4.3% and operating margin of 8.2% suggest limited pricing power or high operational costs relative to revenue. Extremely low return metrics (ROE 0.4%, ROA 0.3%) indicate inefficient capital deployment despite strong balance sheet. ChatGPT: Very low gross margin (8.2%) indicates pricing/COGS pressure. Low ROE (2.3%) and ROA (1.7%) suggest inefficient capital use.
What is RGEN's revenue and growth?
Repligen Corp. reported revenue of $194.3M.
Does RGEN pay dividends?
Repligen Corp. does not currently pay dividends.
Where can I find RGEN SEC filings?
Official SEC filings for Repligen Corp. (CIK: 0000730272) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RGEN's EPS?
Repligen Corp. has a diluted EPS of $0.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RGEN a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Repligen Corp. has a BUY rating with 70% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is RGEN stock overvalued or undervalued?
Valuation metrics for RGEN: ROE of 0.4% (sector avg: 15%), net margin of 4.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RGEN stock in 2026?
Our dual AI analysis gives Repligen Corp. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RGEN's free cash flow?
Repligen Corp.'s operating cash flow is $28.3M, with capital expenditures of $4.7M. FCF margin is 12.1%.
How does RGEN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 4.3% (avg: 12%), ROE 0.4% (avg: 15%), current ratio 9.20 (avg: 2).